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Abstract 
Background: Despite the improvement in survival of patients with lupus nephritis (LN) globally, there is sparse 
data from Sri Lanka (SL). The current study aims to describe the clinicopathological findings, treatment response and 
predictors of long-term outcome of patients with WHO class III–IV LN in SL, managed according to the Euro-lupus 
regime.
Results: Of 72 patients, 64 were females. In half of them, LN was diagnosed within the 1st year of the illness. The 
most common presenting feature was sub-nephrotic proteinuria. Sixteen and twenty patients had nephrotic syn-
drome and abnormal renal function respectively at the time of diagnosis. Fifty-four patients (75%) responded to 
the Euro-lupus regimen [CR, 20 (28%); PR, 34(47%)]. Later at 6 months, 65 patients (90%) achieved remission [CR, 
31(43%); PR, 34 (47%)]. Seven patients experienced treatment failure. During the total duration of follow up, 54 
patients remained in complete or partial remission, 26 developed renal relapses, and 19 suffered severe infective 
episodes. Renal relapses were more common in people who achieved partial remission than complete remission. The 
long term renal outcome was not associated with age, sex, severity of proteinuria, class of LN or initial renal function. 
Patients who achieved remission at 6 months had a good long-term outcome.
Conclusions: The demographic and clinical features of WHO class III and IV LN in Sri Lankan patients were similar to 
that reported in the global literature. 75% of patients responded to the Euro-lupus regimen. Therefore, this regime is 
a suitable initial regimen for LN patients in SL. Good long-term renal outcome can be predicted by early response to 
therapy. Further studies are necessary to explore better treatment options for patients who fail to achieve remission 
during initial therapy.
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Background
Systemic lupus erythematosus (SLE) is an autoimmune 
disease which may give rise to multiple organ involve-
ment because of immune complex deposits. Lupus 
nephritis (LN) is a notable complication of SLE occurring 
in 33–55% of cases leading to high morbidity and mor-
tality [1–3]. Asymptomatic proteinuria, nephritic syn-
drome, nephrotic syndrome and rapidly progressive 
glomerulonephritis are some important clinical manifes-
tations of LN. In America and Europe, the ten year renal 
survival rate has improved to 80–90% with the imple-
mentation of current immunosuppressive regimens [4, 
5]. Literature on LN in Sri Lanka (SL) is very limited. 
One observational study carried out in SL showed that 
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69% of patients developed renal involvements during a 
follow up of 3  years. The majority of them had focal or 
diffuse proliferative glomerulonephritis [6]. The current 
study aims to describe the clinicopathological findings, 
treatment response and predictors of long-term outcome 
of patients with WHO class III–IV LN in SL, managed 
according to the Euro-lupus regime.
Methods
Patient selection
This is a retrospective analysis of the demography, clini-
cal features, response to treatment and other compli-
cations in 72 Sri Lankan patients with renal histology 
confirmed WHO class III and IV lupus nephritis (Class 
III; N = 18, Class IV; N = 54) followed up at the Teaching 
Hospital, Kandy during the period January 2005–Decem-
ber 2011. SLE was diagnosed according to the criteria 
given by American College of Rheumatology. Patients 
who had pre-existing chronic kidney disease, pregnancy, 
previous malignancy and diabetes mellitus were excluded 
from the study. The study was approved by the Ethical 
Review Committee of the University of Peradeniya and 
written informed consent was obtained from all patients.
Treatment received
All patients (n = 72) had been initially managed according 
to the Euro-lupus regime with low dose IV Cyclophospha-
mide pulses (6 pulses of IV Cyclophosphamide at a fixed 
dose of 500 mg fortnightly) and tapering dose of Predniso-
lone [7]. All patients had received 3 daily pulses of 500 mg 
of IV Methyl Prednisolone. A dosage of 1  mg/kg/day of 
Prednisolone had been given for 4  weeks, to critically ill 
patients, patients with renal impairment, nephrotic syn-
drome or severe extra-renal disease. Thereafter, the dosages 
were tapered by 10  mg of Prednisolone every month. All 
the other patients had been given a dose of 0.5 mg/kg/day of 
Prednisolone for 4 weeks. The dosage was tapered by 5 mg 
of Prednisolone every month. In all patients, glucocorticoid 
therapy was maintained at 7.5–10 mg of Prednisolone per 
day. After achieving complete or partial remission, they 
had been treated with Azathioprine (1.5–2 mg/kg) (n = 54, 
75%) and maintained on a low dose of Prednisolone. 
Treatment failure patients after initial Euro-lupus regime, 
were treated with Mycophenolate Mofetil (MMF 1 g/day) 
(n = 18, 25%) and low dose Prednisolone.
Definitions
Treatment failure was  defined as any of the following 3 
features:
1. Absence of a primary response
A. For patients with a baseline serum creatinine 
level  >1.3 but  <2.6  mg/dl, absence of a primary 
response was defined as failure of the serum creati-
nine level to decrease to <1.3 mg/dl at 6 months.
B. For patients with a baseline serum creatinine 
level >2.6 mg/dl, absence of a primary response was 
defined as failure of the serum creatinine level to 
improve by 50% at 6 months.
C. For patients with nephrotic syndrome without renal 
impairment (serum creatinine level  <1.3  mg/dl), 
absence of a primary response was defined as the 
persistence of nephrotic syndrome at 6 months.
2. A glucocorticoid-resistant flare (defined as a severe 
flare that did not respond to a 1-month increase in 
the glucocorticoid dosage)
A severe flare was defined as one of the following 3 fea-
tures: 33% increase in serum creatinine level within a 
1-month period, development of nephrotic syndrome, or 
severe systemic disease (severe systemic disease defined as 
central nervous system disease, thrombocytopenia, haemo-
lytic anaemia, lupus pneumonitis, lupus myocarditis, exten-
sive skin vasculitis, or serositis not responding to low-dose 
glucocorticoid). Benign renal flares were defined as appear-
ance of sub-nephrotic proteinuria without increase in serum 
creatinine level or severe systemic disease.
3. A doubling of the serum creatinine level over the 
lowest value reached at any time during the follow up and 
confirmed on 2 consecutive visits 1 month apart.
Complete remission (CR) was defined as 24-h urinary 
protein level less than 0.3 g/day and normal renal func-
tion (serum creatinine level <1.3 mg/dl) with an inactive 
urinary sediment.
Partial remission (PR) was defined as a urinary sedi-
ment with less than 10 red blood cells per high-power 
field,  ≤25% increase in baseline creatinine, and  ≥50% 
reduction in baseline proteinuria to ≤1.5 g/day.
End points
Renal functions had been assessed on a regular basis 
monthly in all patients up to 1 year. However, further fol-
low up was possible in only 61 patients as 11 were lost 
to follow up. The total duration of follow up varied from 
1 to 6  years. The primary end point was treatment fail-
ure, which was defined as one of the following 3 features: 
absence of a primary response after 6 months of therapy, 
occurrence of a glucocorticoid-resistant flare, or a dou-
bling of the serum creatinine level. Secondary end points 
were the rate of renal remissions and the number of 
severe flares.
Statistical analysis
Results are expressed as means and standard deviations 
(SD) when presenting summary measures of continuous 
variables. Categorical variables are presented as numbers 
Page 3 of 6Herath et al. BMC Res Notes  (2017) 10:80 
and percentages. Data analysis was done using Minitab 
(version 14) statistical software by means of measures of 
central tendencies and appropriate application of para-
metric and non-parametric statistics. Determination of 
different categories and number of patients were done as 
per the definitions given above. Association of different 
parameters with renal outcomes (CR, PR) was achieved 
by using the Student’s t test (age), Chi square test (level 
of proteinuria, initial kidney function, etc.) and Fisher’s 
exact test (gender, number of relapses etc.). P values of 
less than 0.05 were regarded as statistically significant.
Results
Of 72 patients, 64 (89%) were females and the mean age 
of the total cohort was 28  years (range 13–60  years). In 
37(51%) patients, LN was diagnosed within one year fol-
lowing the diagnosis of SLE. The commonest presentation 
was sub-nephrotic proteinuria (n = 56, 78%). Sixteen (22%) 
presented with nephrotic syndrome and 20 (28%) had 
abnormal renal function (serum creatinine >1.3 mg/dl).
Fifty-four patients (75%) responded to the  Euro-lupus 
regimen [CR, 20 (28%); PR, 34 (47%)]. Later at 6 months, 
65 patients (90%) achieved remission [CR, 31(43%); PR, 
34 (47%)]. Seven patients (10%) experienced treatment 
failure. Of them three patients (4%) progressed to end 
stage renal disease and four patients (6%) had experi-
enced doubling of serum creatinine. Eleven patients 
(15%) were lost to follow up. There  was  no significant 
difference between CR and PR in relation to the class of 
lupus nephritis at 1 year or during total duration of fol-
low up (Fisher’s exact test; P values  =  0.401 and 0.301 
respectively) (Table 1).
The total number of relapses during follow up was 26 
(36%). A higher proportion of relapses were seen among 
the patients who achieved PR than CR (P < 0. 05). Long 
term renal outcome (CR, PR) as per the number of 
patients available at present (current status), was not 
associated with age, sex, level of proteinuria or kidney 
function at diagnosis (Table  2). Patients who achieved 
CR or PR with immunosuppressive therapy at 6 months 
showed good long-term outcome (P value  =  0.003). 
Severe infections were reported in 19 patients in our 
study.
Discussion
Renal involvement is often a cause of significant morbid-
ity and mortality in SLE. In most studies, renal involve-
ment was found in approximately one half of patients 
with SLE [1, 8]. The young age of onset of LN and female 
predominance in our series is comparable to other stud-
ies [4, 8, 9]. The majority had renal involvement within 
the 1st year of onset of SLE, as has been reported in other 
studies too [4, 8, 9].
There are some similarities of clinical and biochemi-
cal features in patients in our study and the Euro lupus 
nephritis trial (ELNT) [7]. In our study, 28% of patients 
had abnormal renal functions at diagnosis and 22% had 
nephrotic syndrome as the presenting feature and in the 
ELNT study, the figures were 22 and 28% respectively 
[7]. In both studies, patients had proliferative LN in one 
dominant race (our patient population was Sri Lankan 
and ELNT study mainly consisted of Caucasians). The 
rate of renal remission in the ELNT study was 71% which 
was similar to that observed in our patients (75%) after 
the Euro-lupus regimen. However; we achieved high 
renal remission of up to 90% which may be due to the 
introduction of different treatment regime for those who 
had treatment failure after initial treatments. Further 
studies are necessary to explore better treatment options 
for these patients with treatment failure.
The number of renal relapses in our study and ELNT 
were 36 and 27% respectively. More relapses were seen 
among the patients who achieved PR than CR. A major-
ity of patients experienced renal flare, while they were on 
Azathioprine. Because a very selective and small number 
of patients were given MMF, we could not compare the 
effectiveness of MMF over Azathioprine. This needs fur-
ther studies in SL.
Infections as a sequel to immunosuppressive ther-
apy have been reported as a fairly common problem in 
our region [8, 10–12]. Severe infective episodes were 
reported only in 19 patients in our study. It is possible 
that the rate of infection is much higher than that men-
tioned here, due to under reporting of such episodes 
managed at local hospitals or by general practitioners.
Many studies [13–17] have already described poor 
prognostic factors. These include young age of onset of 
nephritis, African American ethnicity, hypertension, 
renal impairment at onset of LN, and poor pathologic 
findings on kidney biopsy [13–17]. A few studies have 
analysed whether the initial response to therapy predicts 
long-term renal outcome. Levey et  al., found that treat-
ment response was prognostic in a cohort of 63 patients 
with severe lupus nephritis [16]. Houssiau and colleagues 
have demonstrated that an early response to therapy at 
6  months is the best predictor of good long-term renal 
outcome [13]. Our study also confirms that the long term 
renal outcome can be predicted by good response to 
therapy at 6 months.
From these results, we can confirm that the Euro-Lupus 
regimen is a suitable initial regimen for LN patients in 
SL. Use of alternative therapy in remission induction 
and maintenance is beneficial in patients who responded 
poorly to the Euro-lupus regimen.
There are some limitations in our study. This is a ret-
rospective study in one race with a small sample size. A 
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very selective and small number of patients were given 
MMF. Six patients who achieved partial remission were 
lost to follow up. In addition, steroid dosing was not uni-
form in all patients. These factors could have influenced 
the final result.
Conclusions
The demographic and clinical features of WHO class 
III and IV LN in Sri Lankan patients were similar to 
that reported in the global literature. 75% of patients 
responded to the Euro-lupus regimen. Therefore, this 
regime is a suitable initial treatment for LN patients in 
SL. This study confirms that good long term renal out-
come can be predicted by early response to therapy. Fur-
ther studies are necessary to explore better treatment 
options for patients who fail to achieve remission during 
initial therapy.
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